Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Optimizing establishment of high need pediatric Acute Myeloid Leukemia (AML) patient derived xenograft (PDX) models

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMax RochetteSGS GollapudiASAlexandra M. Stevens

Discussion

Loading...

Member takes

Overview

Observational analysis improved engraftment rates in pediatric acute myeloid leukemia, highlighting the need for novel xenograft models.

Key Points

  • Four of twelve viable samples successfully engrafted, demonstrating a 33% success rate in pediatric acute myeloid leukemia.
  • Acute myeloid leukemia flow markers used to assess engraftment through bone marrow and peripheral blood analysis.
  • Using immunodeficient mice, engrafted cells were viably banked for future use and genomic validation.
  • Findings suggest need for improved models for high-risk pediatric acute myeloid leukemia genetic subtypes to expedite evaluation of new treatments.

Cite This Study

Rochette et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dccdhttps://doi.org/10.1182/blood-2025-1515
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A human IL-6–Expressing PDX model of multiple myeloma recapitulates clinical features and supports patient-derived tumor engraftment2025
  2. 2A defined culture model for ex vivo expansion of primary AML cells preserves leukemic stem cells and clonal architecture for functional and therapeutic studies2025
  3. 3Establishing a pediatric solid tumor PDX biobank for precision oncology research2025 · 4 citations
  4. 4NUP98-rearranged pediatric AML is sustained by a conserved leukemia stem cell program with SPNS2/3 as a targetable vulnerability2025
  5. 5Human iPSC-derived bone marrow organoids for AML engraftment and immunotherapy testing2025